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A B S T R A C T
Volumetric absorptive microsampling (VAMS) is a novel sampling technique that allows the
straightforward collection of an accurate volume of blood (approximately 10 mL) from a drop or pool
of blood by dipping an absorbent polymeric tip into it. The resulting blood microsample is dried and
analyzed as a whole. The aim of this study was to evaluate the potential of VAMS to overcome the
hematocrit bias, an important issue in the analysis of dried blood microsamples. An LC-MS/MS method
for analysis of the model compounds caffeine and paraxanthine in VAMS samples was fully validated and
fulﬁlled all pre-established criteria. In conjunction with previously validated procedures for dried blood
spots (DBS) and blood, this allowed us to set up a meticulous comparative study in which both
compounds were determined in over 80 corresponding VAMS, DBS and liquid whole blood samples.
These originated from authentic human patient samples, covering a wide hematocrit range (0.21–0.50).
By calculating the differences with reference whole blood concentrations, we found that analyte
concentrations in VAMS samples were not affected by a bias that changed over the evaluated hematocrit
range, in contrast to DBS results. However, VAMS concentrations tend to overestimate whole blood
concentrations, as a consistent positive bias was observed. A different behavior of VAMS samples
prepared from incurred and spiked blood, combined with a somewhat reduced recovery of caffeine and
paraxanthine from VAMS tips at high hematocrit values, an effect that was not observed for DBS using a
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66 P.M.M. De Kesel et al. / Analytica Chimica Acta 881 (2015) 65–73very similar extraction procedure, was found to be at the basis of the observed VAMS-whole blood
deviations. Based on this study, being the ﬁrst in which the validity and robustness of VAMS is evaluated
by analyzing incurred human samples, it can be concluded that VAMS effectively assists in eliminating
the effect of hematocrit.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Owing to distinct advantages over traditional liquid blood
samples (whole blood, serum and plasma), dried blood spot (DBS)
sampling has been increasingly applied over the last years in
various bioanalytical areas including preclinical animal studies [1–
3] and clinical trials [4] in drug development programs,
therapeutic drug monitoring [5,6] and toxicology [7,8]. Imple-
menting dried blood microsamples in an analytical workﬂow may
simplify sample collection, transport, storage and processing.
Furthermore, it enables collection of representative samples in the
patient’s home setting or in resource-limited areas. Nevertheless,
several issues are still limiting the generalized use of DBS in routine
bioanalysis, amongst which the inﬂuence of hematocrit (Hct) is
one of the most addressed topics, along with the volume of blood
spotted onto the ﬁlter paper cards and the spot homogeneity. As
Hct is directly related with blood viscosity, a drop of blood with
high Hct will spread less on ﬁlter paper, resulting in spots with a
smaller diameter. Consequently, a ﬁxed-sized sub-punch taken
from a high Hct DBS will contain a higher amount of blood (and
analyte) than a punch taken from a low Hct DBS, giving rise to a
Hct-dependent assay bias [9–11]. Apart from the latter phenome-
non, high Hct levels may negatively impact the recovery of an
analyte from DBS, an effect that can be minimized by optimizing
the extraction conditions [12,13].
Several strategies to cope with the Hct effect caused by
differential spreading of blood on ﬁlter paper have been proposed
in the past few years [10,14]. In general, for every sub-punch DBS
method, the impact of Hct can be minimized by preparing the
calibration line using blood with a Hct value close to the expected
median Hct of the study population. Furthermore, by analyzing
quality control (QC) samples prepared from blood with varying Hct
values during method validation, a Hct interval can be established
in which assay bias is within acceptable limits. To verify whether
the Hct of a given DBS actually lies within this interval, potassium
(K+) concentrations can be measured in extracts of DBS as they
allow to predict the Hct of the blood used to prepare the DBS [15].
These predicted Hct values, or the K+ concentrations as such, can
actually be used to correct for the Hct-induced bias [16,17]. An
alternative approach is to use devices, consisting of a multilayered
membrane ﬁltration system, that generate dried plasma spots
(DPS) upon application of blood [18,19]. Although also these
systems hold promise to overcoming the Hct issue, their validity
and practical applicability needs to be supported by more data.
Analyzing complete volumetrically applied DBS is perhaps the
simplest way to avoid the Hct effect [20]. Here, the blood can be
applied on pre-punched paper discs [12,21,22] or, alternatively, the
entire DBS can be punched [23]. However, these approaches
require the accurate and precise application of a ﬁxed volume of
blood onto the ﬁlter paper substrate using pipettes or micro-
capillaries. Whereas this is a feasible strategy when sampling is to
be carried out by trained personnel, it precludes, e.g., home-
sampling by non-experienced individuals.
Recently, two interesting new approaches that allow to collect a
ﬁxed volume of blood from a non-volumetrically deposited sample
have been developed. The ﬁrst is a microﬂuidic device consisting of
a foldable support system that holds a DBS card on one side and a
microﬂuidic plate with sized capillaries on the other [24]. Thesecond, termed volumetric absorptive microsampling (VAMS),
allows straightforward collection of an accurate volume of blood
without the need for specialized devices, such as pipettes or
capillaries. The device consists of a plastic handler with attached to
it an absorbent polymeric tip, which, when dipped into blood,
wicks up an accurate volume of blood (10 mL) [25]. By sampling
blood with Hct values ranging from 0.20 to 0.70, it has been shown
that the absorbed blood volume was independent of Hct [25]. In
addition, analysis of VAMS samples with a similar Hct range (0.20–
0.65) in six different laboratories revealed an acceptable variability
in absorbed blood volume (8.7% CV) [26]. Very recently, VAMS was
used in a toxicokinetic (TK) study in rats. Although controlling the
blood ﬂow rate from the tail vein appeared to be an issue, leading
to overﬁlling of the VAMS tips, the authors concluded that TK
parameters for paracetamol obtained by VAMS were comparable
to those measured in conventional diluted whole blood micro-
samples [27]. Based on these studies, VAMS shows promise to
overcome the Hct and volume bias in the analysis of dried blood
microsamples, while maintaining the beneﬁts of collecting dried
samples. Furthermore, in contrast to sub-punch DBS methods,
potential sample inhomogeneity is no longer an issue as the entire
tip is extracted. However, up to now, only artiﬁcial human samples
(obtained via spiking blood that was prepared to have a certain
Hct) have been used to demonstrate the ability of VAMS to
overcome the Hct effect [25–27]; the impact of Hct on the analysis
of real life human samples remained to be established. Therefore,
the aim of this study was to evaluate the potential of VAMS to
eliminate the Hct effect by analyzing over 80 incurred human
patient samples with a wide Hct range (0.21–0.50). This is the ﬁrst
in-human study in which analyte concentrations obtained by
VAMS are compared to concentrations measured in corresponding
whole blood and DBS samples. The analyzed samples originated
from patients admitted to 18 different hospital departments,
including critical units, such as surgery or burn wound center, and
consultation departments of diverse disciplines, such as radiology,
cardiology, nephrology or oncology. Therefore, in addition to
deviating Hct values, it was expected that this study batch includes
a wide variety of sample characteristics, representing a highly
relevant study batch to evaluate the practical applicability and
robustness of VAMS. Caffeine and paraxanthine, determined
using a validated LC-MS/MS method, were selected as model
compounds since we previously observed that DBS sub-punch
concentrations of both compounds are subject to a Hct-induced
bias [16,28].
2. Materials and methods
2.1. Chemicals and stock solutions
Caffeine, paraxanthine, their internal standards (IS) caffei-
ne-13C3 and paraxanthine-13C4–15N3 and formic acid were
purchased from Sigma–Aldrich (Diegem, Belgium). LC–MS grade
methanol was obtained from Biosolve (Valkenswaard, The
Netherlands). Ultrapure water was provided by a Synergy1Water
Puriﬁcation System (Merck Millipore, Overijse, Belgium). Stock
solutions of caffeine and paraxanthine in water (1 mg mL1) and
the IS in methanol (100 mg mL1) were prepared as described
before [29].
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Caffeine- and paraxanthine-free venous whole blood from a
caffeine abstinent healthy volunteer was collected in ethyl-
enediaminetetraacetic acid (EDTA) tubes (Venosafe1 9 mL VF-
109SDK, Terumo, Leuven, Belgium) and used to prepare calibrators
and QC samples. Patient whole blood samples (n = 96) with a wide
Hct range (0.21–0.50) were obtained by taking aliquots (400 mL)
from EDTA blood samples (Venosafe1 4 mL VF-054SDK, Terumo)
admitted to the Laboratory of Clinical Biology of Ghent University
Hospital for routine analysis. All samples were anonymized and,
apart from Hct values and hospital departments, no clinical
parameters or patient data were available. Hct was measured using
a Sysmex XE-5000 hematology analyzer (Sysmex, Kobe, Japan).
This procedure was approved by the Ethics Committee of Ghent
University Hospital.
VAMS devices (brand name MitraTM) were purchased from
Phenomenex (Utrecht, The Netherlands). VAMS samples were
generated by dipping the upper part of the tip into a volume of
whole blood contained in 2 mL tubes, thereby ensuring that the
tips were not completely immersed into the blood to prevent
overﬁlling. Upon turning completely red, the tips were held in
place for an additional 2 s. Subsequently, the devices were
positioned in a dedicated rack to prevent samples from touching
each other while being air-dried for 2 h at room temperature. DBS
samples were prepared by spotting 25 mL whole blood on
WHA10334885 Whatman 903 ﬁlter paper (GE Healthcare, Dassel,
Germany) using a calibrated pipette and dried under the same
conditions as VAMS samples. Whole blood samples were obtained
by transferring 50 mL blood to 2 mL tubes. Until analysis, dried
samples were stored at room temperature in the presence of
desiccant (two 5 g Minipax1 absorbent packets, Sigma–Aldrich) in
a closed plastic box or a zip-closure plastic bag for VAMS and DBS
samples, respectively. Liquid blood samples were stored at 20 C
for 41 days.
2.3. Sample preparation and LC-MS/MS procedures
VAMS tips were separated from the handler and placed in 2 mL
cups before 140 mL of a methanol/water (80/20, v/v) mixture,
containing 0.01% formic acid and the isotopically labeled IS of
caffeine and paraxanthine, was added. The tips were extracted for
10 min in a Thermomixer1 comfort (Eppendorf, Hamburg,
Germany) set at 1000 rpm and 22 C. Following a centrifugation
step at room temperature (10 min; 10,000  g), 90 mL of the
supernatant was isolated and mixed with 390 mL of water,
containing 0.01% formic acid. The resulting mixture was trans-
ferred to an LC vial and 10 mL was injected onto the UPLC1 column.
DBS and whole blood samples were processed using previously
developed and validated methods [29].
All samples were analyzed by LC-MS/MS using an Acquity
UPLC1 (Waters, Milford, MA, USA)—API 4000TM triple quadrupole
mass spectrometer (AB SCIEX, Framingham, MA, USA) conﬁgura-
tion. Chromatography and mass spectrometry parameters for DBS
and whole blood analysis are described elsewhere [29]. Instrument
settings for analysis of VAMS samples were identical as those for
DBS.
2.4. Validation of the VAMS method
Validation of the VAMS method was based on European
Medicines Agency (EMA) and U.S. Food and Drug Administration
(FDA) guidelines for bioanalytical method validation [30,31] and
included evaluation of selectivity, carry-over, lower limit of
quantiﬁcation (LLOQ), linearity, precision, accuracy, matrix effect,
recovery and stability.Selectivity was assessed by analyzing VAMS samples that were
prepared using blank whole blood from six different healthy
volunteers. Blank samples, along with zero (IS-spiked blank
matrix) samples, were also analyzed at the start of every analytical
run to verify whether the IS potentially contributed to the
responses of the analytes as a result of impurity. All resulting
chromatograms were inspected for interfering peaks, which were
considered acceptable if responses were less than 20% of the LLOQ
for the analytes and 5% for the IS [30]. Blank samples injected after
the highest calibrators were used to determine carry-over, thereby
applying identical criteria as for assessment of selectivity.
On four non-consecutive days, eight-point calibration lines
were constructed using blank whole blood and analyzed to
evaluate linearity. The concentrations of the calibrators were
0.050, 0.075, 0.25, 0.50, 1.0, 2.5, 5.0, 10.0 mg mL1 for caffeine and
0.025, 0.050, 0.100, 0.25, 0.50, 1.0, 2.5, 5.0 mg mL1 for para-
xanthine. The LLOQ was the lowest calibrator and was deﬁned as
the lowest concentration of caffeine and paraxanthine which could
be measured with %RSD and %bias below 20%. To evaluate whether
the obtained calibration data were homoscedastic, an F-test was
performed at the 99% conﬁdence level and residual vs. nominal
concentration plots were constructed [32]. Both unweighted and
weighted linear regression were applied to ﬁnd the best ﬁtted-
model. The following weighting factors were tested: 1/x,1/x2,1/
p
x,
1/y, 1/y2 and 1/
p
y. The obtained models were compared by
calculating the sum% relative error (RE) and plotting %RE against
nominal concentrations [32]. In order to accept the selected model,
mean back-calculated concentrations of the calibrators should be
within 15% of the nominal value or within 20% for the LLOQ
[30].
QCs at four concentration levels were prepared and analyzed in
duplicate on four non-consecutive days to determine precision and
accuracy. The nominal concentrations were 0.05 and 0.025 (LLOQ),
0.12 and 0.06 (low), 4.0 and 2.0 (medium), 8.0 and 4.0 (high)
mg mL1 for caffeine and paraxanthine, respectively. Independent
stock solutions were used for QCs and calibrators. For all spiked
samples, the volume of non-matrix solvents never exceeded 5% of
the total sample volume. A single factor ANOVA was used to
calculate intra- and interbatch precision values (%RSD) [33].
Accuracy (%bias) was calculated by dividing the difference
between the obtained concentration and the nominal value by
the nominal value and multiplying it by 100. Precision and
accuracy should be within 15% (20% for the LLOQ) [30].
Blank whole blood originating from six different sources with
Hct values ranging from 0.40 to 0.46 (0.43  0.02; mean  SD) was
used to determine matrix effect and recovery. Blood samples were
spiked at low and high concentration level before (C) or after (B)
extraction. Solutions of caffeine and paraxanthine in the starting
eluent at the same concentrations (A) were prepared as well. To
prepare solutions A and B, a nominal blood volume of 10 mL,
absorbed by the VAMS tips when dipped into the blood samples,
was taken into account. The ratios of peak areas of (B) to those of
(A) were multiplied by 100 to obtain absolute matrix effect values,
while absolute recovery values were calculated by multiplying the
ratios of peak areas of (C) to those of (B) by 100. Relative matrix
effect and recovery were obtained by the %RSD of absolute matrix
effect and recovery values [34]. Relative matrix effect should not
exceed 15% [30]. To evaluate the impact of Hct on recovery and
matrix effect, blood samples with different Hct values (0.21, 0.42
and 0.62) were prepared starting from blood with Hct 0.48, as
described before [15]. For all four Hct levels, recovery and matrix
effect were determined in triplicate on low and high concentration
level. Here, 10 mL of blank or spiked blood was spotted onto the
upper surface of the VAMS tips using a calibrated pipette.
Stability of VAMS samples was evaluated by analyzing low and
high QCs in triplicate at time point zero and after 4 days of storage
Table 1
Calibration and sensitivity data for the determination of caffeine and paraxanthine in VAMS samples using LC-MS/MS (n = 4).
Weighting Slope, mean  SD [95% CI] Intercept, mean  SD [95% CI] R2 Standard deviation of residuals Range (mg mL1)
Caffeine 1/y2 2.021  0.215 0.036  0.010 0.996 0.250 0.050–10.0
[1.833–2.209] [0.028–0.045]
Paraxanthine 1/x2 4.456  0.480 0.025  0.014 0.995 0.284 0.025–5.0
[4.035–4.877] [0.012–0.037]
Table 2
Intra- and inter-batch precision and accuracy (n = 4  2) for QCs of caffeine and paraxanthine at four concentration levels in VAMS samples.
QC Intrabatch precision (%RSD) Interbatch precision (%RSD) Accuracy (%bias)
Caffeine Paraxanthine Caffeine Paraxanthine Caffeine Paraxanthine
LLOQ 8.08 6.65 14.31 13.36 8.96 1.77
Low 7.82 5.68 9.03 7.73 3.48 4.21
Medium 4.84 3.22 5.70 5.38 0.64 1.07
High 3.12 4.30 5.42 5.85 1.63 2.17
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placed in dedicated clamshells and stored in zip-closure plastic
bags with dessicant until analysis. Processed sample stability was
assessed by re-injecting extracts of low and high QCs (n = 3) after
4 days of storage in the autosampler (4 C) and 30 days at 20 C.
All stability samples were analyzed against a freshly prepared
calibration curve. The obtained mean concentrations at a given
time point should be within 15% of the concentration measured
at time point zero and of the nominal concentration [30].
2.5. Comparative study involving VAMS, DBS and whole blood
sampling
Caffeine and paraxanthine concentrations were determined in
VAMS, DBS and whole blood samples originating from 96 hospital
patient blood samples. All samples were analyzed against freshly
prepared matrix-matched calibration curves, prepared from blank
blood from a single donor with a Hct of 0.48. To examine the impact
of Hct on VAMS and DBS results, differences (%) between VAMS or
DBS concentrations and whole blood concentrations were plotted
against Hct values. Percentage differences were calculated by
dividing the difference between VAMS or DBS and whole blood
concentrations by the whole blood concentrations and multiplying
the result by 100. Using least squares regression analysis, linear
regression lines were ﬁtted to the resulting data. Slopes, intercepts
and their 95% conﬁdence intervals (CI) were calculated by the
Analysis Toolpack of MS Excel1 2013 (Microsoft, Redmond, WA,
USA). VAMS and whole blood concentrations were also compared
by constructing Bland–Altman plots using Medcalc statistical
software version 12.7.5 (Medcalc Software bvba, Ostend, Belgium).
Furthermore, caffeine and paraxanthine concentrations were
determined in VAMS and whole blood samples (n = 3) originating
from spiked and incurred blood. Therefore, blank EDTA blood from
a healthy volunteer was spiked with caffeine and paraxanthine toTable 3
Absolute and relative matrix effect and recovery data (n = 6) for caffeine and paraxanthin
different individuals with Hct values ranging from 0.40 to 0.46 (0.43  0.02; mean  SD
Absolute matrix effect (mean  SD, %) Relative matrix effect (%RSD
QC Without IS With IS Without IS With IS
Caffeine
Low 101.71  3.23 98.27  3.87 3.17 3.94 
High 102.50  1.23 100.08  1.18 1.20 1.18 
Paraxanthine
Low 99.79  5.09 99.81  5.68 5.10 5.69 
High 101.09  1.08 99.44  1.71 1.07 1.72 obtain nominal concentrations of 1.0 and 0.8 mg mL1, respectively.
These target concentrations were based on the results of a
previously conducted CYP1A2 phenotyping study [28] and should
approximate whole blood caffeine and paraxanthine concentra-
tions 6 h after the intake of a 150 mg caffeine test dose. Hence, on
the same day, a second blood sample was collected from the same
volunteer 6 h after oral ingestion of a capsule containing 150 mg
caffeine. Spiked and incurred samples were analyzed in the same
analytical run. Calibration curves for VAMS and whole blood
samples were prepared using a single pool of blank blood.
3. Results and discussion
3.1. Validation of the VAMS method
No unacceptable interfering peaks were observed in VAMS
samples prepared from blank blood from 6 individual sources and
the IS did not contribute to the responses of caffeine and
paraxanthine. Furthermore, no carry-over was found in blank
samples injected after the highest calibrators. Calibration data for
caffeine and paraxanthine were found to be heteroscedastic.
Weighted linear regression considerably improved %RE values
compared to unweighted regression. The selected weighting
factors for both compounds are shown in Table 1, together with
calibration and sensitivity data. Using these regression parameters,
mean back-calculated concentrations of the calibrators deviated
less than 5 and 7% from the nominal concentrations for caffeine
and paraxanthine, respectively. The chosen models fulﬁlled the
acceptance criteria and the calibration lines were linear. Intra- and
interbatch precision (%RSD) and accuracy (%bias) values for
caffeine and paraxanthine, displayed in Table 2, were below 15%
and, therefore, also met the acceptance criteria.
Table 3 shows matrix effect and recovery data for caffeine and
paraxanthine, determined in VAMS samples prepared frome at two concentration levels in VAMS samples prepared using whole blood from six
).
) Absolute recovery (mean  SD, %) Relative recovery (%RSD)
 Without IS With IS Without IS With IS
99.10  4.33 116.42  6.10 4.37 5.24
94.04  2.60 108.73  2.77 2.77 2.55
90.16  3.71 100.20  2.66 4.11 2.66
87.74  2.34 95.74  2.01 2.66 2.10
Table 4
Absolute recovery and matrix effect data (n = 3) for caffeine and paraxanthine at two concentration levels in VAMS samples prepared using whole blood with varying Hct
values.
Hct Caffeine Paraxanthine
Low QC High QC Low QC High QC
Absolute recovery (mean  SD, %) 0.21 101.45  2.26 101.79  0.67 86.98  1.52 87.14  1.75
0.42 101.30  1.28 100.53  2.67 84.70  3.53 84.33  1.38
0.48 93.86  0.89 91.08  2.03 75.48  0.60 75.93  1.09
0.62 92.01  4.80 92.91  4.74 73.51  1.60 77.72  5.69
Absolute matrix effect (mean  SD, %) 0.21 104.29  3.37 100.49  1.54 101.46  2.49 99.69  2.01
0.42 101.16  0.53 99.52  1.71 98.28  3.28 99.48  0.34
0.48 97.46  0.50 97.48  0.99 99.03  2.73 99.10  1.31
0.62 103.07  2.09 98.36  0.31 100.58  4.26 99.48  1.78
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absolute matrix effect for both compounds was close to 100%, with
or without compensation by the IS. Relative matrix effect, being
lower than 4 and 6% RSD for caffeine and paraxanthine,
respectively, was well within the predeﬁned acceptance limits
(15% RSD). High recovery values (>87%) were obtained for both
compounds. As recovery was somewhat lower for the IS than for
the analytes, a slight overcompensation for caffeine was observed
when the IS was taken into account. However, it should be noted
that, in order to calculate the amount of analyte that was spiked
after extraction, a nominal absorbed blood volume of 10 mL was
assumed. According to the manufacturer, the average absorbed
volume of the VAMS tips used in this study was actually 10.7 mL.
Therefore, the reported recovery values in Table 3 represent a
limited overestimation of the real recovery. Importantly, recovery
for both compounds was reproducible (<6% RSD). As the blood
samples used in the latter experiment had a narrow Hct range
(0.40–0.46), the effect of Hct on recovery and matrix effect was
further evaluated using blood samples with deviating Hct values
(0.21–0.62). Absolute recovery and matrix effect values, deter-
mined in triplicate at low and high concentration levels, are
presented in Table 4. For these data, compensation by the IS was
already taken into account. While matrix effect was not affected by
Hct recovery for both compounds was lower at higher Hct values
(0.48 and 0.62). A similar trend was observed by Denniff et al., who
found a reduced recovery for low paracetamol concentrations in
VAMS samples, with recovery values ranging from 92.9 to 70.6%
over a comparable Hct range (0.20–0.69) [27]. It seems that as Hct
increases, the higher relative amount of erythrocytes trapped in
the VAMS tips renders it more difﬁcult for compounds to be
desorbed from the tips. Since 10 mL of blood was directly spotted
onto the VAMS tips in this experiment, it can be excluded that
lower volumes of blood absorbed by the tips were at the basis of
the reduced recovery at high Hct. Although beyond the scope of
this study, this recovery issue can most probably be resolved by
optimizing the extraction conditions, for example by using
sonication [12] or elevated extraction temperatures [13], as
demonstrated in DBS analysis. Here, we opted to apply a very
similar protocol as previously developed and validated for theTable 5
Stability data for caffeine and paraxanthine in VAMS samples at two concentration
levels (n = 3). Data are presented as the percentage of the concentrations measured
at time point zero.
QC Room temperature 82 days (mean  SD,
%)
60 C 4 days (mean  SD, %)
Caffeine Paraxanthine Caffeine Paraxanthine
Low 100.10  11.24 97.44  10.38 97.58  8.64 90.94  8.28
High 99.11  3.50 99.41  4.92 94.09  7.08 95.50  5.09extraction of caffeine and paraxanthine from DBS and for which a
suchlike inﬂuence of Hct on recovery was not observed [29].
Stability data for low and high QCs, analyzed in triplicate, are
presented in Table 5 and demonstrate that caffeine and para-
xanthine were stable in VAMS samples for at least 82 days when
stored at room temperature and for at least 4 days when stored at
60 C, the latter representing potential shipping conditions.
Furthermore, processed samples were stable when stored for at
least 4 days in the autosampler set at 4 C and for at least 30 days at
20 C. Stock solutions of both compounds and the IS were stable
for at least 6 months at 20 C [29].
3.2. Comparative study involving VAMS, DBS and whole blood
sampling
In 81 out of 96 corresponding VAMS, DBS and whole blood
samples, caffeine concentrations above the LLOQ (0.050 mg mL1)
could be measured, while paraxanthine concentrations above the
LLOQ (0.025 mg mL1) were measured in 83 samples. As we relied
on daily consumption of caffeine containing beverages or food to
determine caffeine and paraxanthine concentrations in the
collected samples, no data on caffeine dose or time since the last
intake were available. The latter, combined with the availability of
a single blood sample per subject, did not allow to calculate
pharmacokinetic parameters. Hct values in the analyzed samples
ranged from 0.21 to 0.50, with a median of 0.36. It should be noted
that all samples were analyzed against calibration curves prepared
using blood with a Hct of 0.48. We speciﬁcally opted to use a
calibration curve generated from blood with a relatively high Hct to
clearly visualize the Hct effect on DBS concentrations and create a
worst case scenario, both for DBS and VAMS samples. This allows a
challenging assessment of the Hct effect. The differences (%)
between VAMS or DBS concentrations and whole blood concen-
trations, plotted against Hct values, are shown in Fig. 1 for caffeine
(a) and paraxanthine (b). A similar Hct-induced bias was observed
for DBS concentrations of both compounds, as regression lines
ﬁtted to the differences between DBS and whole blood concen-
trations had a slope of 83.67 (95% CI; [67.80–99.54]) and an
intercept of 46.30 (95% CI; [52.17 to 40.44]) for caffeine and a
slope of 82.25 (95% CI; [67.61–96.90]) and an intercept of 52.16
(95% CI; [57.57 to 46.75]) for paraxanthine. Measured DBS
concentrations markedly decreased with decreasing Hct values.
These results are in accordance with previous ﬁndings for both
compounds [16]. With differences between DBS and whole blood
concentrations ranging from 35.52 to 8.39% for caffeine and from
41.44 to 4.16% for paraxanthine over the evaluated Hct range, the
assay bias was unacceptable at low Hct levels. However, as we
previously demonstrated [16], DBS concentrations of both com-
pounds can be corrected for the Hct bias in a convenient way by
means of an algorithm based on K+ concentrations measured in
Fig. 1. Differences (%) between VAMS (white dots) or DBS (black dots) concentrations and whole blood concentrations plotted against hematocrit for (a) caffeine (n = 81) and
(b) paraxanthine (n = 83). Broken lines represent linear regression lines.
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affected by a suchlike Hct-effect. The regression lines ﬁtted to the
differences between VAMS and whole blood concentrations had a
slope of 1.70 (95% CI; [26.96–23.56]) and an intercept of 14.09
(95% CI; [4.76–23.43]) for caffeine and a slope of 5.98 (95% CI;
[28.42–16.47]) and an intercept of 19.13 (95% CI; [10.84–27.42])
for paraxanthine. As, for both compounds, the 95% CIs of the slopes
included the 0 value, it can be concluded that the differences
between VAMS and whole blood concentrations did not change in
function of Hct (in the range between 0.21 and 0.50). These
ﬁndings on real patient samples lend support to other studies
using artiﬁcial samples, demonstrating that VAMS devices are able
to collect an accurate volume of blood over a wide Hct range
[25,26].
Remarkably, VAMS concentrations were subject to a consistent
positive bias, irrespective of Hct. Bland–Altman plots for the
differences between VAMS and whole blood concentrations (Fig. 2)
revealed a mean positive difference of 12.3% (95% CI; [10.5–14.1%])
and 15.4% (95% CI; [13.9–16.9%]) for caffeine and paraxanthine,
respectively. Thus, analyte concentrations determined in VAMS
samples tend to overestimate whole blood concentrations,
although deviations were relatively limited, taking into account
that results from different matrices (i.e., dried VAMS tips vs. liquid
whole blood), obtained by different extraction procedures and
analyzed in separate analytical runs, were compared. For example,
for 86 and 74% of the samples for caffeine and paraxanthine,respectively, differences between VAMS and whole blood con-
centrations were below 20%, thereby fulﬁlling the acceptance
criteria of incurred sample reanalysis, intended for reanalysis of a
single matrix [30]. Interestingly, a positive bias for VAMS results
was also described by Denniff et al. [27]. In a paracetamol TK study
in rats, mean Cmax was up to 40% higher when measured in VAMS
samples compared to diluted whole blood samples. The authors
concluded that this bias was caused by a combination of overﬁlled
VAMS tips, as a result of the rate of blood ﬂow from the tail vein
being higher than the rate at which tips could absorb the blood,
and the fact that VAMS and whole blood samples were collected
from different groups of animals. In another study, the authors
found a signiﬁcant positive bias for midazolam when VAMS tips
were intentionally submerged into blood past the shoulder [25]. In
our study, we paid special attention to avoid overﬁlling of the tips.
All VAMS samples were prepared by dipping the tip into a small
volume of blood (400 mL) contained in 2 mL plastic tubes,
enabling good visibility of the blood surface, by operators
experienced in handling blood (micro) samples. Care was taken
to prevent that VAMS tips were dipped too deeply into the blood
samples.
The differences observed in our study may be attributed to a
combination of factors. First, from an analytical point of view, the
recovery of caffeine and paraxanthine from VAMS samples was
reduced at higher Hct values, as discussed in Section 3.1. Data in
Table 4 show that the recovery of both compounds was lower
Fig. 2. Bland–Altman plots for the comparison between VAMS and whole blood concentrations for (a) caffeine (n = 81) and (b) paraxanthine (n = 83). Mean differences and
limits of agreement (LoAs) are represented by full lines, 95% conﬁdence limits by broken lines.
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0.48 and 0.62. The latter also applies for the recovery data at the
lower evaluated Hct levels (0.21 and 0.42). Importantly, the patient
samples in our study were analyzed against calibrators prepared
from blood with Hct 0.48. However, all but two patients samples
had Hct values below 0.48, with 0.21 being the lowest Hct.
Consequently, analyte concentrations in patient VAMS samples
will have been consistently overestimated, albeit to a limited
extent, due to the difference in recovery between calibrators and
study samples. Hence, although VAMS results were not subject to a
“traditional Hct effect”, with lower concentrations measured at
low Hct levels and higher concentrations at high Hct values, as seen
in DBS analysis, Hct did have an impact on the analysis of VAMS
samples, by affecting the recovery. We consider it unlikely that
other analytical factors contributed to the disparity between VAMS
and whole blood concentrations. Hct had no effect on ion
suppression or enhancement for VAMS samples. The different
types of samples were analyzed against calibration curvesprepared in the respective matrices. Accuracy values (%bias) for
QCs of caffeine and paraxanthine in liquid whole blood and VAMS
samples were within 5% (9% at LLOQ level). Furthermore, under
the storage conditions used here, both compounds were stable in
whole blood and VAMS samples for prolonged periods of time,
exceeding the storage times the actual study samples were subject
to. Apart from the evaluation of the stability of caffeine and
paraxanthine in VAMS samples reported here, a whole blood
stability experiment was previously performed and described
elsewhere [29]. Caffeine and paraxanthine proved to be stable in
whole blood for at least 172 days when stored at 20 C. From a
methodological point of view, several additional factors may have
played a role. First of all, the observed mean differences between
VAMS and whole blood concentrations (12.3 and 15.4% for caffeine
and paraxanthine, respectively) are highly comparable to the mean
differences previously found between plasma and whole blood
concentrations (15.2 and 16.6 for caffeine and paraxanthine,
respectively) [28]. This might lead one to hypothesize that VAMS
Table 6
Caffeine and paraxanthine concentrations in VAMS and whole blood samples (n = 3) originating from spiked and incurred blood. Blank EDTA blood from a healthy volunteer
was spiked with caffeine and paraxanthine to obtain nominal concentrations of 1.0 and 0.8 mg mL1, respectively. Incurred blood was collected on the same day from the same
volunteer 6 h after oral ingestion of a capsule containing 150 mg caffeine.
VAMS (mg mL1) mean  SD (%CV) Whole blood (mg mL1) mean  SD; (%CV) Difference VAMS-whole blood (%)
Caffeine Spiked samples 1.03  0.01 [1.36] 1.01  0.01 [1.31] 1.49
Incurred samples 1.12  0.01 [1.07] 1.04  0.02 [1.74] 6.86*
Paraxanthine Spiked samples 0.81  0.01 [1.45] 0.81  0.01 [0.62] 0.35
Incurred samples 0.82  0.02 [1.95] 0.77  0.01 [0.88] 6.35*
* Signiﬁcant difference (p < 0.05).
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and that the resulting VAMS concentrations would reﬂect plasma
rather than whole blood concentrations. However, by comparing
the hemoglobin content of VAMS tips prepared using the standard
dipping technique to that of tips to which 10 mL of blood was
spotted, Denniff et al. demonstrated that there is no indication for
such an effect [25]. Furthermore, the positive bias of VAMS vs.
whole blood may result from the fact that measured whole blood
concentrations underestimated the actual values, instead of VAMS
concentrations overestimating whole blood concentrations. In this
light, we veriﬁed whether whole blood samples were completely
hemolyzed by the applied sample preparation procedure [29].
During validation of the whole blood method, QCs of caffeine and
paraxanthine at four concentration levels, stored at 80 C for
90 min and thawed at room temperature, were analyzed in
duplicate on three different days along with freshly prepared QCs.
As for dried VAMS samples, hemolysis was considered to be
complete in frozen and thawed blood samples. The resulting
caffeine and paraxanthine concentrations are summarized in
Supplementary Table S1. No signiﬁcant differences between
caffeine and paraxanthine concentrations in fresh and hemolyzed
blood were found; all differences were within 3%. These results
exclude that potential incomplete hemolysis of blood samples may
have contributed to the observed deviations. Interestingly, we
observed an apparently differential behavior of VAMS samples
prepared from incurred vs. spiked blood. Table 6 shows caffeine
and paraxanthine concentrations measured in VAMS and whole
blood samples (n = 3) originating from either spiked blank blood or
blood collected 6 h after the administration of a 150 mg caffeine
dose. For both compounds, no signiﬁcant differences were found
between spiked whole blood and corresponding VAMS samples.
Analyte concentrations in incurred blood, however, were higher
when measured in VAMS compared to whole blood samples.
Although differences were limited (6.86 and 6.35% for caffeine and
paraxanthine, respectively), these were statistically signiﬁcant, as
determined by independent samples t-tests (p = 0.005 and
0.008 for caffeine and paraxanthine, respectively). Therefore, we
concluded that the latter effect, for which the underlying reason is
unknown, combined with the somewhat reduced recovery of
caffeine and paraxanthine from VAMS samples at the Hct of the
calibration line used for analysis of the study samples, was at the
basis of the observed positive difference between VAMS and whole
blood results.
4. Conclusion
VAMS, a novel sampling technique that allows to accurately
collect a ﬁxed volume of blood, represents a promising approach to
overcome the effect of deviating Hct values in the analysis of dried
blood microsamples. In this study, the potential of VAMS to
effectively eliminate the Hct bias was evaluated by analyzing over
80 VAMS samples prepared from incurred whole blood collectedfrom hospital patients displaying a wide Hct range (0.21–0.50).
Therefore, an LC-MS/MS method for the determination of caffeine
and paraxanthine in VAMS tips was fully validated. All evaluated
parameters met the pre-established criteria. Analyte concentra-
tions in VAMS samples were compared to corresponding DBS and
whole blood concentrations. VAMS results were not affected by a
bias that changed in function of Hct as differences between
caffeine and paraxanthine concentrations in VAMS and whole
blood samples did not vary over the evaluated Hct range, in
contrast to the observed DBS-blood differences. However, on the
other hand, it should be noted that measured VAMS concentrations
consistently overestimated whole blood concentrations. It was
found that this effect was caused by a combination of a different
behavior of VAMS samples prepared from incurred or spiked blood
and a reduced recovery of the analytes from VAMS tips at high Hct
values. Interestingly, in a previous study, the latter effect was not
observed for DBS, although very similar procedures were used to
extract caffeine and paraxanthine from DBS and VAMS samples. On
the basis of this study, it can be concluded that VAMS indeed allows
to overcome the Hct bias for caffeine and paraxanthine, although
care should be taken when protocols developed for DBS analysis
are transferred to VAMS samples. As this study is the ﬁrst in which
the usefulness of VAMS is evaluated based on results obtained from
real incurred human samples, our ﬁndings should be compared to
those for other compounds with varying characteristics, deter-
mined using validated procedures, in order to further accept VAMS
as a reliable sampling technique in bioanalysis.
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